Navigating the CDMO landscape for fill/finish services can be complex and time-consuming, from evaluating capability to compliance, quality, and expertise. How selecting the right CDMO partner can help position your liquid and powder sterile products for success at each stage of the development process. Join industry experts as they share key strategies for accelerated formulation development and examine the impact of revised EU GMP Annex-1 regulations and PUPSIT on CDMO capability and selection.
Learn what to look for when assessing a sterile fill/finish CDMO for your next project, including how facility design and equipment impact sterility assurance and quality. Our speakers will discuss the specialist expertise required to support sterile powder and liquid development, providing actionable insights on technology transfer, formulation optimization, and regulatory considerations that can streamline your path to clinical trials.
This webinar is designed specifically for biotechs in early-stage development (Phase 1-Phase 2 clinical trials) currently evaluating CDMOs to support their sterile drug product development. Attendees will gain valuable perspectives on risk mitigation strategies, quality control parameters, and compatibility considerations that are essential when selecting a partner for these critical services. Whether you’re working with biologics, small molecules, or complex formulations, this session will equip you with the knowledge to make informed decisions about your sterile manufacturing partnerships.
By ticking this box, you consent to receiving communications from Upperton related to this topic and other products or services within their portfolio